CADTH Canadian Drug Expert Committee recommendation: Etonogestrel extended-release subdermal implant (Nexplanon -- Merck Canada Inc.) indication : prevention of pregnancy for up to three years
Etonogestrel extended-release subdermal implant has a Health Canada indication for the prevention of pregnancy. Etonogestrel is the biologically active metabolite of desogestrel, a progestagen widely used in oral contraceptives. This radiopaque implant is a longacting hormonal contraceptive that con...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, October 2020
|
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Etonogestrel extended-release subdermal implant has a Health Canada indication for the prevention of pregnancy. Etonogestrel is the biologically active metabolite of desogestrel, a progestagen widely used in oral contraceptives. This radiopaque implant is a longacting hormonal contraceptive that contains 68 mg of etonogestrel. The Health Canada-approved dose is for a single implant that is inserted subdermally and can be left in place for three years |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (9 pages) |